Bincy Abraham, MD, MS

Articles by Bincy Abraham, MD, MS

Take-Home Messages for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 11th 2023

Experts in gastroenterology share advice for the treatment of patients of Crohn’s disease.

Emerging Therapies and Challenges for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 4th 2023

Dr Anita Afzali and Miguel Regueiro discuss emerging therapies and combinations in the pipeline for Crohn’s disease as well as unmet needs in the field for disease management.

Role of Biosimilars for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 4th 2023

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, comment on emerging data for interchangeability of biosimilars and biologics when treating Crohn’s disease.

Using Selective IL-23 Inhibitors for the Treatment of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 28th 2022

Experts in gastroenterology review the use of IL-23 inhibitors such as guselkumab and risankizumab-rzaa for the management of Crohn’s disease.

Selecting Treatment Options for Elderly Patients in Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 28th 2022

Dr Bincy P. Abraham examines age considerations and comorbidities when choosing a therapy for elderly patients with Crohn’s disease.

Real-World Implications of Novel Crohn’s Disease Therapies

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 21st 2022

Anita Afzali, MD, MPH, MHCM, FACG, AGAF, explores clinical implications of newer therapies for Crohn’s disease in the real-world setting.

Durability of IL-12/23 Inhibitors in Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 21st 2022

Jennifer Seminerio, MD, discusses long-term outcomes and clinical remission rates for patients on an IL/23 inhibitor for Crohn’s disease.

IL-23 Inhibitors and IL-12/23 Inhibitors for Crohn’s Disease Management

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 14th 2022

Dr Miguel Regueiro comments on the safety and efficacy of approved IL-23 inhibitors and IL-12/23 inhibitors for the treatment of Crohn’s disease.

Role of IL 12/23 Inhibitors for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 14th 2022

Jennifer Seminerio, MD, and Bincy P. Abraham, MD, MS, AGAF, FACG, share their perspective on the use of IL-12/23 inhibitors in clinical practice for the management of Crohn’s disease.

Treatment Selection for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 7th 2022

Drs Bincy P. Abraham, Miguel Regueiro, David P. Hudesman, Anita Afzali, and Jennifer Seminerio provide insight on approaching the optimal therapy for patients with Crohn’s disease in the frontline and second-line settings.

Using Biologics in Crohn’s Disease Treatment

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 7th 2022

Drs Miguel Regueiro, Jennifer Seminerio, Anita Afzali, and David Hudesman review currently available biologic therapies for moderate-to-severe Crohn’s disease and the evolution of the disease treatment landscape.

Approaching Treatment for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 30th 2022

Dr Bincy P. Abraham leads a discussion on factors to consider when selecting a therapy for the management of Crohn’s disease.

Goals of Therapy for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 30th 2022

Experts in gastroenterology review goals of therapy for the management of Crohn’s disease, utilizing a treat-to-target approach for treatment, and the importance of shared decision-making.

Diagnosis of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 23rd 2022

Dr Anita Afzali and Dr Bincy P. Abraham review the diagnostic workup for Crohn’s disease and challenges in diagnosing the disease.

Overview of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 23rd 2022

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, provide insight on the pathophysiology of Crohn’s Disease (CD), associated risk factors, and diagnosis of disease.

Advice for Physicians to Manage C. Difficile Infection (CDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

October 12th 2022

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Unmet Needs in Management of C. Difficile Infection (CDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

October 12th 2022

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Differences Between Fecal Microbiota Transplantation Studies to Treat C. Difficile Infection (CDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

October 12th 2022

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

October 5th 2022

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

October 5th 2022

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 28th 2022

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Foundational Trials for Fecal Microbiota Transplantation for C. difficile Infection

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 28th 2022

Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.

Monitoring Patients with C. difficile Infection (CDI) and rCDI

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 21st 2022

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Fecal Microbiota Transplantation (FMT) for Treatment of C. difficile Infection (CDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 21st 2022

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

Treatment Options for C. difficile Infection (CDI)

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 14th 2022

Experts review treatment options for first, second and recurring episodes of C. difficile infection (CDI).

Long-Term Impact of C. difficile Infection (CDI) and Infection Recurrence

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 14th 2022

A gastroenterologist reviews long-term impact of dysbiosis and C. difficile infection (CDI).

Gut Microbiota and Consequences of Gut Microbiota Disruption

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 7th 2022

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

Diagnosis and Management of C. difficile Infection (CDI) in Patients with Inflammatory Bowel Disease

ByPaul Feuerstadt, MD,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS

September 7th 2022

Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.